Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Commission grants Orphan Drug Designation to Alexion Pharmaceuticals Inc's Soliris


Wednesday, 23 Apr 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:European Commission has granted orphan drug designation (ODD) to Soliris.Soliris is first-in-class terminal complement inhibitor, for prevention of graft rejection following solid organ transplantation. 

Company Quote

171.295
-3.455 -1.98%
3:42pm EDT